Corona Virus Disease 2019 (COVID-19) is a respiratory tract infection caused by an emerging β-coronavirus which is named Sever Acute Respiratory Syndrome Corona Virus 2 (SARS-COV-2). Worldwide human to human swift transmission of the virus generated a global pandemic [1]. Noticing urgency, the World Health Organization (WHO) on 20 March announced a megatrial study named SOLIDARITY to repurpose drugs that have already been in use for treatment of other viral diseases and malaria. One of the SOLIDARITY choices is a combination of two anti-HIV drugs plus interferon-β (IFN-β) [2].
Interferons are a family of cytokines best known for their anti-viral effects. They play a critical role in slowing down of viral multiplication. These cytokines are subdivided into three types. The type I IFNs (IFN-α/β) possess 13 members including IFN-α/β. The type II IFN has just one member, IFN-γ. The type III IFNs (IFN-λ) are made up of 4 members namely IFN-λ1 to IFN-λ4. According to the recent investigations all three types of interferons can either activate or regulate immune response [3], [4]. Although type I and type III IFNs have even more immune activities in common, their functions are not fully redundant and IFN-λs have specific characteristics which may make them an appropriate therapy against COVID-19:
-
1-
While the expression of type I IFNs receptors are ubiquitous, the expression of IFN-λ receptors are limited to the tissues with relatively high numbers of epithelial cells such as lung, skin, gastrointestinal and respiratory tracts. This dual pattern of receptors distribution gives a unique potential to the IFN-λ family for tailored targeting special tissues [5].
-
2-
The yin-yang concept is seen in each medicinal component. Application of both type I and type III IFNs is followed by a range of side effects [6]. Nonetheless, due to the restricted expression of the IFN-λ family receptors, fewer side effects would be expected. In addition, the type I IFNs have a central role in lung inflammatory response [7].
-
3-
At mucosal surfaces IFN-λ family plays a significant role in driving anti-viral immune response [8].
-
4-
During a mouse Influenza A infection, IFN-λ and not IFN-α was chiefly produced by intranasal epithelial cells [9].
-
5-
In a mouse model, both IFN-λ and IFN-α could prevent Influenza virus replication, however, only IFN-λ could hinder spreading of the virus to the lung [10].
Previously, low-dose IFN-α prophylaxis could reduce the severity of acute respiratory illness during an influenza pandemic [11]. It seems IFN-λ therapy could be advantageous during COVID-19 pandemic if it is locally administrated directly to mucosal barriers where the earliest anti-viral defense occurs with less inflammatory side effects. [12].
Declaration of Competing Interest
The authors declare that they have no conflict of interest.
References
- 1.Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
- 2.Kupferschmidt K., Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367(6485):1412–1413. doi: 10.1126/science:367.6485.1412. [DOI] [PubMed] [Google Scholar]
- 3.Lee A.J., Ashkar A.A. The dual nature of type I and type II interferons. Front Immunol. 2018;9:2061. doi: 10.3389/fimmu.2018.02061. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.McNab F., Mayer-Barber K., Sher A., Wack A., O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87–103. doi: 10.1038/nri3787. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Sommereyns C. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008;4(3) doi: 10.1371/journal.ppat.1000017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Parker D. Impact of Type I and III interferons on respiratory superinfections due to multidrug-resistant pathogens. J Infect Dis. 2017;215(suppl_1):S58–S63. doi: 10.1093/infdis/jiw466. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Makris S., Paulsen M., Johansson C. Type I interferons as regulators of lung inflammation. Front Immunol. 2017;8:259. doi: 10.3389/fimmu.2017.00259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Ye L., Schnepf D., Staeheli P. Interferon-lambda orchestrates innate and adaptive mucosal immune responses. Nat Rev Immunol. 2019;19(10):614–625. doi: 10.1038/s41577-019-0182-z. [DOI] [PubMed] [Google Scholar]
- 9.Bennett A.L. Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year. Influenza Other Respir Viruses. 2013;7(5):854–862. doi: 10.1111/irv.12094. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Klinkhammer J. IFN-lambda prevents influenza virus spread from the upper airways to the lungs and limits virus transmission. Elife. 2018;7 doi: 10.7554/eLife.33354. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Jewell N.A. Lambda interferon is the predominant interferon induced by influenza A Virus infection in vivo. J Virol. 2010;84(21):11515–11522. doi: 10.1128/JVI.01703-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Lazear H.M., Schoggins J.W., Diamond M.S. Shared and Distinct Functions of Type I and Type III Interferons. Immunity. 2019;50(4):907–923. doi: 10.1016/j.immuni.2019.03.025. [DOI] [PMC free article] [PubMed] [Google Scholar]